Adaptimmune Therapeutics Plc Capital Reinvestment Ratio
Adaptimmune Therapeutics Plc capital reinvestment ratio. Adaptimmune Therapeutics Plc (ADAP) has a Capital Reinvestment Ratio of 0.02x as of June 2024, meaning it reinvests 0% of its operating cash flow ($47.39 Million) in capital expenditures ($754.55K). Check ADAP capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Adaptimmune Therapeutics Plc (2013–2021)
Capital reinvestment ratio of Adaptimmune Therapeutics Plc from 2013 to 2021. This chart tracks Adaptimmune Therapeutics Plc's Capital Reinvestment Ratio across 2 annual periods. Also explore ADAP year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Adaptimmune Therapeutics Plc Capital Reinvestment Ratio by Year (2013–2021)
Adaptimmune Therapeutics Plc capital reinvestment ratio by year from 2013 to 2021. For the full cash flow conversion analysis, see Adaptimmune Therapeutics Plc cash flow conversion.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2021 | 0.82x | $10.73 Million | $8.78 Million | ▲ +2002.4% |
| 2013 | 0.04x | $37.23 Million | $1.45 Million | — |